Favipiravir gets nod

Payal Banerjee

New Delhi

India's drug regulator has approved anti-viral drug favipiravir for "restricted emergency use" in mild to moderate cases of COVID-19, official sources said, as instances of coronavirus infection and fatalities in the country continued its steady upward trend.

Considering the emergency and unmet medical need for COVID-19, the Drug Controller General of India (DCGI) under the fast-tracked approval process granted domestic firm Glenmark Pharmaceuticals the permission to manufacture and market favipiravir (200 mg) tablet.

FPJ Shorts

Thane Traffic Update: Major Road Closures In Sadar Area For Uddhav & Raj Thackeray Event Ahead Of BMC Elections 2026; Complete Advisory Inside

Mana Shankara Vara Prasad Garu X (Twitter) Review: 'Mass With Class', Chiranjeevi-Nayanthara Starrer Receives Positive Response From Netizens

Amsterdam Streets Turns Into Ice Rink: Funny Visuals Of Pedestrians Struggling To Move & Skidding On Roads Go Viral - Watch

Mumbai BMC Elections 2026: 'Who Are Aaditya & Raj Thackeray To Threaten Me?' K Annamalai Hits Back At MNS Chief's 'Lungi' Remark

"The drug has been approved for restricted emergency use in the country for the treatment of mild to moderate cases of COVID-19," an official source in the know of developments told PTI.

Following this approval, Mumbai-headquartered Glenmark Pharmaceuticals will make a separate application to state regulators to get a manufacturing license under the provisions of the Drugs and Cosmetics Act and its rules.